MXPA03001528A - Improved specificity in treatment of diseases. - Google Patents

Improved specificity in treatment of diseases.

Info

Publication number
MXPA03001528A
MXPA03001528A MXPA03001528A MXPA03001528A MXPA03001528A MX PA03001528 A MXPA03001528 A MX PA03001528A MX PA03001528 A MXPA03001528 A MX PA03001528A MX PA03001528 A MXPA03001528 A MX PA03001528A MX PA03001528 A MXPA03001528 A MX PA03001528A
Authority
MX
Mexico
Prior art keywords
drug
blocking group
reduction
diseases
treatment
Prior art date
Application number
MXPA03001528A
Other languages
Spanish (es)
Inventor
Johnson Lau
Original Assignee
Ribapahrm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribapahrm Inc filed Critical Ribapahrm Inc
Publication of MXPA03001528A publication Critical patent/MXPA03001528A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052—Imidazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A drug is modified by covalently coupling a blocking group to the drug via a nitrogen atom in the blocking group. The blocking group in the modified drug prevents metabolic conversion and sequestration of the drug in non-target cells, and the blocking group is enzymatically removed in the target cell. Particularly contemplated advantages of presented compounds and methods include reduction of cytotoxicity by inhibition of metabolic conversion to potentially cytotoxic metabolites, reduction of dosages of drugs by reduction of sequestration into non-target cells, and increase of selectivity of a drug.
MXPA03001528A 2000-08-22 2000-12-07 Improved specificity in treatment of diseases. MXPA03001528A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22687100P 2000-08-22 2000-08-22
US22687000P 2000-08-22 2000-08-22
US22694800P 2000-08-22 2000-08-22
PCT/US2000/033454 WO2002016382A1 (en) 2000-08-22 2000-12-07 Improved specificity in treatment of diseases

Publications (1)

Publication Number Publication Date
MXPA03001528A true MXPA03001528A (en) 2004-04-02

Family

ID=27397667

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03001528A MXPA03001528A (en) 2000-08-22 2000-12-07 Improved specificity in treatment of diseases.

Country Status (15)

Country Link
EP (1) EP1351966A1 (en)
JP (1) JP2004518618A (en)
KR (1) KR20030040415A (en)
CN (1) CN1460109A (en)
AU (1) AU2001220806A1 (en)
BR (1) BR0017318A (en)
CA (1) CA2416748A1 (en)
CZ (1) CZ2003460A3 (en)
HU (1) HUP0302882A3 (en)
IL (1) IL154168A0 (en)
MX (1) MXPA03001528A (en)
NO (1) NO20030762L (en)
PL (1) PL365879A1 (en)
TW (1) TW200414903A (en)
WO (1) WO2002016382A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516548A (en) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト Drug delivery from rapidly gelled polymer compositions
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
CN100448879C (en) * 2004-07-22 2009-01-07 北京化工大学 Method for preparing unformed cefuroxime axetil

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE29835E (en) * 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
US3798209A (en) * 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
US3984396A (en) * 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US3991078A (en) * 1971-06-01 1976-11-09 Icn Pharmaceuticals, Inc. N-substituted 1,2,4-triazoles
US4093624A (en) * 1977-01-31 1978-06-06 Icn Pharmaceuticals, Inc. 1,2,4-Thiadiazolidine-3,5-dione
JPS6426593A (en) * 1987-07-21 1989-01-27 Asahi Glass Co Ltd Nucleoside derivative
US4925930A (en) * 1988-11-02 1990-05-15 Nucleic Acid Research Institute Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates

Also Published As

Publication number Publication date
HUP0302882A2 (en) 2003-12-29
WO2002016382A1 (en) 2002-02-28
HUP0302882A3 (en) 2005-06-28
KR20030040415A (en) 2003-05-22
BR0017318A (en) 2004-06-15
NO20030762L (en) 2003-04-22
CA2416748A1 (en) 2002-02-28
JP2004518618A (en) 2004-06-24
CN1460109A (en) 2003-12-03
IL154168A0 (en) 2003-07-31
NO20030762D0 (en) 2003-02-18
AU2001220806A1 (en) 2002-03-04
EP1351966A1 (en) 2003-10-15
TW200414903A (en) 2004-08-16
PL365879A1 (en) 2005-01-10
CZ2003460A3 (en) 2003-10-15

Similar Documents

Publication Publication Date Title
GEP20053688B (en) Substituted-Triazolopyrimidines as Anticancer Agents
EG25822A (en) Quinolinyl-pyrrolopyrazoles
CZ309247B6 (en) 40-O- (2-hydroxyethyl) rapamycin for use as the sole active ingredient in treating a solid tumour
NZ514574A (en) Novel method of treatment
GEP20063799B (en) Tropane derivatives useful in therapy
AU2005202257C1 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
BG103641A (en) Derivatives of arylsulphonylhydroxamic acid
DK1030670T3 (en) Use of vitamin D derivatives to enhance the action of cytotoxic agents
AP2001002288A0 (en) Methods for treatment of sickle cell anemia.
PT1309315E (en) VALDECOXIB RAPID DISINTEGRATION ORAL FORMULA
HK1086186A1 (en) Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain
CY1107465T1 (en) MELAGATRANI FOR THERAPEUTIC INFECTION
EP1622586A4 (en) Process for preparing tannate tablet capsule or other solid dosage forms
MX2007006637A (en) Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1.
CA2377373A1 (en) Nitric oxide donors for inducing neurogenesis
DE60031686D1 (en) PYRAZINONE, COMPOSITIONS CONTAINING THESE COMPOUNDS
MXPA03001528A (en) Improved specificity in treatment of diseases.
GEP20043231B (en) Resorcinol Composition
MXPA01012936A (en) Pharmaceutical composition containing sibutramine and orlistat.
AU4258601A (en) Divided dose therapies with vascular damaging activity
EP1347754A4 (en) Compositions for adhesion prevention
WO2002040477A3 (en) Saframycins, analogues and uses thereof
WO2001007029A3 (en) Substituted guanidines and the use thereof
MY126998A (en) Substituted pyrroles.
WO2001076597A3 (en) A method of administering an antitumour compound using a polymer-camptothecin conjugate